Randomised phase II trial of photodynamic therapy plus oral fluoropyrimidine, S-1, versus photodynamic therapy alone for unresectable hilar cholangiocarcinoma

Do Hyun Park(Massachusetts Institute of Technology), Jung Bok Lee(Asan Medical Center), Hee Jung Choi, Sung Koo Lee(Ulsan College), Dong Wan Seo(Dankook University), Jae‐Lyun Lee(Ulsan College), Hyoung Jung Kim(University of Ulsan), Sang Soo Lee(Chungbuk National University Hospital), June Ho Choi(Ulsan College), Ji Woong Jang(Eulji University), Jun Bum Eum(Ulsan College), Myung-Hwan Kim(Ulsan College), Soeun Park(Ulsan College)
European Journal of Cancer
March 27, 2014
10.1016/j.ejca.2014.01.008
Cited by 110

Related Papers

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
|JAMA Oncology|2017|846
TIMP-2 Mediated Inhibition of Angiogenesis
|Cell|2003|510
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Oncology|2020|502
Practice of endoscopy during COVID-19 pandemic: position statements of the Asian Pacific Society for Digestive Endoscopy (APSDE-COVID statements)
|Gut|2020|332